{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-052715","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.286953+00:00","generated_at":"2026-06-08T04:37:26.726126+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Gyre Therapeutics presents Hydronidone preclinical data at AASLD; plans US clinical program in 2024","bullets":["Poster at AASLD Liver Meeting (Nov 10-14, 2023) shows Hydronidone reduces liver fibrosis in mouse models.","Hydronidone inhibits hepatic stellate cell activation via Smad7-mediated TGF-β degradation.","Company expects to initiate U.S. clinical program for MASH-associated fibrosis in 2024.","Specific Smad7 knockdown in vivo blocked Hydronidone's antifibrotic effect, confirming mechanism."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-052715","json":"https://secwatch.observer/filing/0001140361-23-052715.json","markdown":"https://secwatch.observer/filing/0001140361-23-052715.md","text":"https://secwatch.observer/filing/0001140361-23-052715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123052715/0001140361-23-052715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123052715/ny20009756x16_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:37:26.726126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}